Ocugen Gene Therapy Hits Targets, Disappoints Investors
Ocugen Gene Therapy Hits Phase 2 Goals Yet Investor Sentiment Falters In the high-stakes world of biotech, hitting clinical trial endpoints is the primary goal. Yet, as Ocugen, Inc. recently demonstrated, a clear scientific win doesn’t always translate to Wall Street applause. The company announced that its investigational gene therapy, OCU400, successfully met its primary […]
Ocugen Gene Therapy Hits Targets, Disappoints Investors Read More »



